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What is it? Physiological E2F is a
heterodimer composed of an E2F
subunit together with a DP subunit.
There are six published members
of the E2F family that are divided
into three sub-groups based upon
sequence homology and domain
organization. Each E2F subunit has
a DNA binding and dimerization
domain. E2F-1, -2, -3 each have an
extended amino-terminal region
that binds CyclinA/Cdk2 kinase
and, like E2F-4 and -5, a carboxy-
terminal transcription activation
domain (TAD) that also provides an
interface for the pocket proteins
pRb, p107 or p130. E2F-6 lacks a
TAD and may be a transcriptional
repressor. There are two DP
subunits and most E2F
heterodimers contain DP-1.
How does it work? The E2F DNA
binding domain is a winged
helix–turn–helix; it binds the
consensus DNA sequence
TTT(C/G)(C/G)CGC. E2F activates
transcription, requiring an
interaction between the TAD and
p300/CBP coactivators.
What does it do? E2F activity
coordinates gene expression as
cells progress from G0 into G1 and
S phase. E2F targets are required for
cell cycle progression, (regulatory
proteins such as Cyclins E and A
and Cdc2), for DNA replication
(Cdc6, ORC1 and MCM6) and for
DNA synthesis (enzymes such as
dihydrofolate synthetase, DNA
polymerase α and thymidine kinase).
E2F also regulates apoptotic genes
such as Arf, p73 and Apaf1.
How is E2F regulated? E2F is
regulated by members of the
pocket protein family, such as
pRb, which bind to the TAD. This
interaction is under
phosphorylation control of pRb,
and is mediated by the G1 cyclin-
dependent kinases (Cdk)
CyclinD/Cdk4 and CyclinE/Cdk2.
So E2F is a transcriptional
activator and repressor? E2F
can exist in at least three different
states: active, inactive and
repressive. Free E2F is the active
form, and inactive E2F results
from the association of a pocket
protein. Repressive E2F requires
chromatin-regulating and
remodelling proteins, including
histone deacetylase (HDAC),
SWI/SNF, polycomb group
proteins (PCG) and histone
methlytransferase (MTase).
Are all E2Fs the same? E2F-1 to
-5 activate transcription. E2F-1 to -
3 bind pRb, and E2F-4 and -5 bind
p107 or p130, and these
interactions are under cell cycle
control. The combined loss of E2F-
1, -2 and -3 abolishes S phase
entry in fibroblasts, whereas E2F-
4–/– and E2F-5–/– cells have defects
in cell cycle exit. The phenotype of
knockout mice with inactivated
E2F genes are strikingly different.
E2F-1–/– mice appear
developmentally normal, but have
defects in apoptosis in the immune
system, and tumours develop in
old animals. Most E2F-3–/–
embryos die in utero; E2F-4–/– mice
have aberrant erythrocyte
maturation and E2F-5–/– mice
develop neurological defects such
as hydroencephaly. DP-1 is an
essential gene.
Is E2F affected in tumour cells?
E2F activity is under aberrant
control in most, if not all, human
tumour cells through alteration or
mutation of genes required to
control the pRb–E2F interaction,
such as Rb, CyclinD and the p16
locus.
Oncogene or tumour
suppressor? E2F-1 has
oncogenic properties in vivo and
in vitro. E2F-1 can induce
apoptosis through p53-dependent
and -independent mechanisms.
E2F-1 is stress-responsive, and is
regulated by the phosphatidyl
inositol-3-kinase-like kinase family
such as ATM/ATR kinases.
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Figure 1. 
In non-proliferating cells, the E2F/DP heterodimer binds pocket proteins such as pRb.
During early cell cycle progression G1 cyclin-dependent kinase complexes (Cyclin
D/Cdk4 and Cyclin E/Cdk2) phosphorylate pRb, releasing E2F. E2F becomes tran-
scriptionally active through interaction with transcription cofactors such as p300/CBP.
In tumour cells, mutant pRb fails to bind E2F. Similarly, viral oncoproteins bind pRb to
hinder its interaction with E2F. In addition, p16 can be inactivated, or cyclin D1 over-
expressed, in cancer cells. The pRb/E2F complex becomes an active transcriptional
repressor by recruiting proteins, such as HDAC, MTase, PCG and SWI/SNF, that alter
the chromatin environment to favour transcriptional inactivity.
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